Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1949 1
1950 1
1992 1
1993 1
1994 3
1999 1
2000 1
2006 3
2007 2
2008 1
2009 2
2011 2
2012 3
2013 3
2014 1
2015 2
2016 3
2017 4
2018 5
2019 2
2020 5
2021 9
2022 4
2024 4
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

59 results

Results by year

Filters applied: . Clear all
Page 1
Co-design with aboriginal and torres strait islander communities: A journey.
Tamwoy N, Rosas S, Davis S, Farthing A, Houghton C, Johnston H, Maloney C, Samulkiewicz N, Seaton J, Tuxworth G, Bat M. Tamwoy N, et al. Among authors: farthing a. Aust J Rural Health. 2022 Dec;30(6):816-822. doi: 10.1111/ajr.12918. Epub 2022 Aug 29. Aust J Rural Health. 2022. PMID: 36037400 Review.
Anhydro-N-carboxy-DL-phenyl-alanine.
FARTHING AC, REYNOLDS RJ. FARTHING AC, et al. Nature. 1950 Apr 22;165(4199):647. doi: 10.1038/165647a0. Nature. 1950. PMID: 15416749 No abstract available.
Laparoscopic Repair of Uteroperitoneal Fistula.
Jones BP, Rajamanoharan A, Trew G, Farthing A. Jones BP, et al. Among authors: farthing a. J Minim Invasive Gynecol. 2020 Sep-Oct;27(6):1241-1243. doi: 10.1016/j.jmig.2019.12.001. Epub 2019 Dec 5. J Minim Invasive Gynecol. 2020. PMID: 31812615 No abstract available.
Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial.
Goodyear CS, Patel A, Barnes E, Willicombe M, Siebert S, de Silva TI, Snowden JA, Lim SH, Bowden SJ, Billingham L, Richter A, Carroll M, Carr EJ, Beale R, Rea D, Parry H, Pirrie S, Lim Z, Satsangi J, Dunachie SJ, Cook G, Miller P, Basu N, Gilmour A, Hodgkins AM, Evans L, Hughes A, Longet S, Meacham G, Yong KL, A'Hearne MJ, Koh MBC, Burns SO, Orchard K, Paterson C, McIlroy G, Murray SM, Thomson T, Dimitriadis S, Goulston L, Miller S, Keillor V, Prendecki M, Thomas D, Kirkham A, McInnes IB, Kearns P; OCTAVE-DUO investigators. Goodyear CS, et al. Lancet Rheumatol. 2024 Jun;6(6):e339-e351. doi: 10.1016/S2665-9913(24)00065-1. Epub 2024 May 8. Lancet Rheumatol. 2024. PMID: 38734019 Free article. Clinical Trial.
59 results